


Piceatannol

Cat. No.:	HY-13518												
CAS No.:	10083-24-6												
Molecular Formula:	C ₁₄ H ₁₂ O ₄												
Molecular Weight:	244.24												
Target:	Syk; Autophagy; Apoptosis												
Pathway:	Protein Tyrosine Kinase/RTK; Autophagy; Apoptosis												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 31 mg/mL (126.92 mM)
 H₂O : 1 mg/mL (4.09 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		4.0943 mL	20.4717 mL	40.9433 mL
	5 mM		0.8189 mL	4.0943 mL	8.1887 mL
	10 mM		0.4094 mL	2.0472 mL	4.0943 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)^[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties^[2]. Piceatannol induces apoptosis in DLBCL cell lines^[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells^[4].

In Vitro

Piceatannol is a resveratrol metabolite^[2].
 SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25, and 50 μM; 72 hours) inhibits cell growth of six diffuse large B cell lymphomas (DLBCL) cell lines (SUDHL-6, U2392, DOHH2, Karpas 422, VAL, OCI Ly19) with IC₅₀s of 18 μM, 25 μM, 37 μM, 48 μM, >50 μM and

>50 μ M, respectively^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[3]

Cell Line:	Six DLBCL cell lines (Karpas 422, VAL, SUDHL-6, OCI Ly19, U2392 and DOHH2)
Concentration:	3.125, 6.25, 12.5, 25, and 50 μ M
Incubation Time:	72 hours
Result:	The IC ₅₀ s were 18 μ M in SUDHL-6, 25 μ M in U2392, 37 mM in DOHH2, 48 μ M in Karpas 422 and higher than 50 μ M in OCI-Ly19 and in VAL.

In Vivo

Piceatannol (10, 20, and 40 mg/kg) inhibits the pulmonary edema and reduces the infiltration of inflammatory cells induced by lipopolysaccharide^[1].

Piceatannol (10, 20, and 40 mg/kg) alleviates the myeloperoxidase activity and inhibits the production of iNOS and COX-2 expressions in lung tissues induced by lipopolysaccharide^[1].

Piceatannol (10, 20, and 40 mg/kg; intraperitoneally 1 h) treatment alleviates inflammatory response by inhibiting the activation of TLR/NF- κ B signaling pathway in lung tissues during acute lung injury (ALI) induced by LPS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (40-50 g) ^[1]
Dosage:	10, 20, and 40 mg/kg
Administration:	Intraperitoneally 1 h before LPS challenge
Result:	Significantly reduced the pulmonary edema induced by LPS.

CUSTOMER VALIDATION

- Cell. 2018 Oct 4;175(2):442-457.e23.
- Nat Commun. 2020 Sep 21;11(1):4765.
- Pharmacol Res. 2020 May;155:104751.
- J Agric Food Chem. 2017 Jun 7;65(22):4384-4394.
- Mol Immunol. 2022 Mar;143:105-113.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lu-Yuan Peng, et al. Protective Effect of Piceatannol Against Acute Lung Injury Through Protecting the Integrity of Air-Blood Barrier and Modulating the TLR4/NF- κ B Signaling Pathway Activation. *Front Pharmacol*. 2020 Jan 22;10:1613.

[2]. Jonathan Kershaw, et al. The Therapeutic Potential of Piceatannol, a Natural Stilbene, in Metabolic Diseases: A Review. *J Med Food*. 2017 May;20(5):427-438.

[3]. Andrea Rinaldi, et al. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. *Hematol Oncol*. 2011 Sep;29(3):164-6.

[4]. Kamila Siedlecka-Kroplewska, et al. Induction of autophagy, apoptosis and acquisition of resistance in response to piceatannol toxicity in MOLT-4 human leukemia cells. *Toxicol In Vitro*. 2019 Sep;59:12-25.

Caution: Product has not been fully validated for medical applications. For research use only.

India Contact:
Life Technologies (India) Pvt. Ltd.
306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444
Email: customerservice@lifetechindia.com Website: www.lifetechindia.com